Technical Analysis for SLRN - Acelyrin Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 7.00 | 4.01% | 0.27 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 200 DMA Resistance | Bearish | 4.01% | |
| Wide Bands | Range Expansion | 4.01% | |
| Overbought Stochastic | Strength | 4.01% | |
| Fell Below 200 DMA | Bearish | 4.32% | |
| Calm After Storm | Range Contraction | 4.32% | |
| Wide Bands | Range Expansion | 4.32% |
| Alert | Time |
|---|---|
| Possible NR7 | about 7 hours ago |
| Possible Inside Day | about 7 hours ago |
| 1.5x Volume Pace | about 7 hours ago |
| 10 DMA Support | about 8 hours ago |
| 60 Minute Opening Range Breakdown | about 8 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/13/2024
Acelyrin Inc. Description
ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.88 |
| 52 Week Low | 3.67 |
| Average Volume | 960,080 |
| 200-Day Moving Average | 6.74 |
| 50-Day Moving Average | 4.85 |
| 20-Day Moving Average | 5.73 |
| 10-Day Moving Average | 6.72 |
| Average True Range | 0.45 |
| RSI (14) | 71.67 |
| ADX | 45.68 |
| +DI | 33.79 |
| -DI | 8.24 |
| Chandelier Exit (Long, 3 ATRs) | 5.90 |
| Chandelier Exit (Short, 3 ATRs) | 5.02 |
| Upper Bollinger Bands | 7.94 |
| Lower Bollinger Band | 3.53 |
| Percent B (%b) | 0.79 |
| BandWidth | 76.86 |
| MACD Line | 0.66 |
| MACD Signal Line | 0.57 |
| MACD Histogram | 0.0935 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.60 | ||||
| Resistance 3 (R3) | 7.57 | 7.33 | 7.50 | ||
| Resistance 2 (R2) | 7.33 | 7.18 | 7.35 | 7.47 | |
| Resistance 1 (R1) | 7.17 | 7.09 | 7.25 | 7.20 | 7.43 |
| Pivot Point | 6.93 | 6.93 | 6.98 | 6.95 | 6.93 |
| Support 1 (S1) | 6.77 | 6.78 | 6.85 | 6.80 | 6.57 |
| Support 2 (S2) | 6.53 | 6.69 | 6.55 | 6.53 | |
| Support 3 (S3) | 6.37 | 6.53 | 6.50 | ||
| Support 4 (S4) | 6.40 |
